Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Heart; Dysfunction Postoperative, Cardiac Surgery
About this trial
This is an interventional treatment trial for Heart; Dysfunction Postoperative, Cardiac Surgery focused on measuring Suppress Atrial Fibrillation, heart bypass surgery, heart valve surgery
Eligibility Criteria
Inclusion Criteria:
- Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able to provide informed consent.
Exclusion Criteria:
- Documented atrial fibrillation within the previous 3 months
- Ongoing therapy with suppressive antiarrhythmic drugs
- Patient currently on digoxin
- Emergent surgery
- Patient receiving hemodialysis
- Concomitant use of ketoconazole, diltiazem, verapamil
- Known tolerance or hypersensitivity to ranolazine
- Pregnant individuals
- MAZE procedure (is a surgical ablation to treat atrial fibrillation) performed during concurrent cardiac surgery
Sites / Locations
- William Beaumont Hospital
- William Beaumont Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
CABG surgery with Ranolazine
CABG surgery with placebo
Heart Valve surgery with Ranolazine
Heart Valve surgery with placebo
Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.